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Abstract
Breast cancer is the most common cancer in women, and this prevalence has a major impact on health worldwide. Localized
breast cancer has an excellent prognosis, with a 5-year relative survival rate of 85%. However, the survival rate drops to only
23% for women with distant metastases. To date, the study of breast cancer metastasis has been hampered by a lack of
reliable metastatic models. Here we describe a novel in vivo model using human breast cancer xenografts in NOD scid
gamma (NSG) mice; in this model human breast cancer cells reliably metastasize to distant organs from primary tumors
grown within the mammary fat pad. This model enables the study of the entire metastatic process from the proper
anatomical site, providing an important new approach to examine the mechanisms underlying breast cancer metastasis. We
used this model to identify gene expression changes that occur at metastatic sites relative to the primary mammary fat pad
tumor. By comparing multiple metastatic sites and independent cell lines, we have identified several gene expression
changes that may be important for tumor growth at distant sites.
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Introduction
Metastatic disease is responsible for greater than 80% of all
deaths from carcinoma [1]. Therefore a central goal of cancer
research is to identify and characterize mechanisms that drive
metastasis, to allow the development of new therapeutic agents to
inhibit metastasis.
Metastasis is a complex process involving multiple steps by
which tumor cells escape from the primary site and disseminate to
form new lesions in other organs. To metastasize, tumor cells must
degrade and cross the extracellular matrix, intravasate, travel
through blood or lymphatic vessels, extravasate at the secondary
site, and finally, establish secondary tumors [2]. To understand
metastasis it is important that research models replicate the many
steps involved in this complex process.
Previous studies into breast cancer metastasis have been limited
by models that poorly replicate the entire metastatic process [3,4].
An ideal model would reproduce the entire metastatic process,
including tumor cell escape and dissemination from the orthotopic
site (i.e., the mouse mammary fat pad), followed by colonization
and outgrowth at distant sites. The most commonly used model of
breast cancer metastasis relies on injecting tumor cells directly into
the circulation via the tail vein or left ventricle of the heart [5,6].
This model removes the requirement for cells to invade and
intravasate, and therefore cannot be used to study the complete
metastatic process. Thus, new models that replicate the metastatic
process in its entirety are required to improve our understanding
of how breast cancer spreads.
Here we describe a new system to study breast cancer metastasis
that models the entire metastatic process. Using orthotopic
injection of human breast cancer cells into the mammary fat pads
of NOD scid gamma (NSG) mice [7], metastases in distant organs
consistently develop without the need for resection of the primary
tumor. Therefore, this model can be used to study the metastatic
process in its entirety. We used this model to identify gene
expression changes that occur in metastatic lesions compared to
the primary tumor. These gene expression changes may regulate
metastatic growth at distant sites and may represent potential
therapeutic targets to inhibit metastatic disease.
Results
NSG mice are highly susceptible to metastasis formation
In order to develop a system that models the entire metastatic
process, we injected aggressive basal MDA-MB-231 human breast
carcinoma cells orthotopically into the mammary fat pads of nine
severely immunocompromised NSG mice. Mice were monitored
for development of primary xenograft tumors and sacrificed when
tumors reached 10% of body weight. Following injection, the
primary mammary fat pad tumors grew rapidly (Figure 1A),
resulting in sacrifice of the mice at day 53 post-injection.
Harvested primary mammary fat pad tumor tissue was immuno-
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histochemically stained for CK18, EGFR and Her2 expression.
MDA-MB-231 primary tumors were CK18 positive, EGFR
positive, Her2 negative (Figure 1B), demonstrating that the
xenograft tumors retained the MDA-MB-231 cell line expression
pattern of key breast cancer markers. At necropsy mice were
examined visually for macro-metastases. Macro-metastases were
frequently and consistently observed in axillary lymph nodes
(100% of mice), lungs (100% of mice), liver (78% of mice), and
diaphragm (67% of mice), as well as sporadically in other organs
(Figure 1C). Organs were harvested and the presence of metastases
was confirmed by H&E and CK18 staining of tissue sections
(Figure 1D).
To determine if this high rate of metastasis was restricted to
MDA-MB-231 cells, we injected twelve NSG mice with another
aggressive basal breast carcinoma cell line, MDA-MB-436.
Similarly to MDA-MB-231 cells, MDA-MB-436 cells rapidly
formed primary tumors in the mammary glands of female NSG
mice (Figure 2A). Similarly to MDA-MB-231, harvested primary
mammary fat pad tumor tissue was immunohistochemically
stained for CK18, EGFR and Her2 expression. MDA-MB-436
primary tumors were CK18 positive, EGFR positive, Her2
negative (Figure 2B), demonstrating that the NSG MDA-MB-
436 xenograft tumors also retained the MDA-MB-436 cell line
expression pattern of key breast cancer markers. Upon necropsy at
day 43 macro-metastases were frequently observed in the lungs
and axillary lymph nodes of tumor bearing mice (Figure 2C).
Organs were harvested and the presence of metastases was
confirmed by H&E and CK18 staining (Figure 2D).
Having confirmed that aggressive basal breast carcinoma cell
lines frequently metastasize in NSG mice, we examined whether
the luminal MCF7 and BT474 breast carcinoma cell lines could
metastasize in this model. Metastases are almost never observed
with these two cell lines in other strains of mice [8]. MCF7 cells
formed slow growing primary tumors in the mammary gland
(Figure 3A) that were CK18 positive, EGFR negative, Her2
negative (Figure 3B). Interestingly MCF7 cells frequently metas-
tasized to the axillary lymph node (67% of mice), lung (25% of
mice), and spleen (25% of mice) (Figure 3C). We also observed
sporadic metastases including a kidney lesion (Figure 3D) and a
large ovarian metastasis, which are very unusual.
BT474 cells formed primary mammary fat pad tumors
(Figure 4A) that were CK18 positive, EGFR positive, Her2
positive (Figure 4B). BT474 cells were much less metastatic in this
model, forming macro-metastases in only a few cases (axillary
lymph node in 17% of mice, and spleen in 8% of mice).
Importantly, these cells come from a solid invasive ductal
carcinoma of the breast with no known metastatic disease [9].
Thus, the metastatic ability of the original tumor is recapitulated
by our model.
We also confirmed that macro-metastasis formation was not
restricted to established cell lines by using a primary breast cancer
culture, dissociated tumor (DT)-16 [10]. Similarly to established
cell lines, DT-16 primary breast cells also frequently metastasized
to the liver (3/3) and lymph nodes (3/3) of NSG mice.
Having determined that MDA-MB-231 and MDA-MB-436
breast cancer cell lines frequently and reliably metastasize to
distant organs in NSG mice, we used these models to examine in
vivo gene expression alterations that occur in metastatic lesions
relative to the primary mammary fat pad tumors.
We compared the gene expression profiles of MDA-MB-231
metastatic lesions from several organs (liver, lung, diaphragm, and
lymph nodes) to the gene expression profile of the primary
xenograft tumor growing in the mammary fat pad of NSG mice.
420 genes were differentially expressed in liver metastases, 56 in
lung metastases, 85 in diaphragm metastases, and 24 in lymph
node metastases, compared to the primary mammary fat pad
tumor (Tables S1, S2, S3, and S4). These differentially expressed
genes were then compared and a single gene, LOC100129599,
was identified as consistently differentially expressed at all
metastatic sites relative to the primary tumor (Figure 5A and
Table S5).
Similarly, the gene expression profile of MDA-MB-436
metastatic lesions growing in lung and lymph nodes were also
compared to the gene expression profile of the primary xenograft
mammary fat pad tumor. 719 genes were differentially expressed
in lung metastases, and 258 in lymph node metastases, compared
to the primary mammary fat pad tumor (Tables S6 and S7). 54 of
the gene expression changes were common to both the lung and
lymph node metastases (Figure 5B and Table S8). LOC100129599
was differentially expressed in the MDA-MB-436 lymph node
metastases relative to the primary mammary fat pad tumor, but
not the lung metastases.
The gene expression changes that occurred in lymph node
metastases relative to primary mammary fat tumor in MDA-MB-
231 xenografts were then compared to those that occurred in
MDA-MB-436 xenografts to detect any commonalities (Figure 5C
and Table S9). Six genes, RPL13A, KLF6, LOC100129599,
GBE1, PDGFA, and UHRF1 were altered in lymph node
metastases of both cell lines relative the primary tumor, suggesting
they may represent changes important for metastatic growth in
lymph nodes.
Similarly, the gene expression changes that occurred in lung
metastases relative to primary mammary fat tumors in MDA-MB-
231 xenografts were compared to those that occurred in MDA-
MB-436 xenografts to detect any commonalities (Figure 5D and
Table S10). 17 probes (16 genes) were altered in lung metastases of
both cell lines relative to the primary tumor suggesting they may
represent changes important for metastatic growth in the lungs.
Discussion
Human breast cancer cell lines derived from tumors with
metastatic capability in the original patient rarely metastasize in
commonly used immunocompromised mouse models, including
nude and NOD SCID mice. This lack of reliable metastasis in vivo
has hampered thorough investigation of the metastatic process.
Our use of NSG mice represents a significant advance, due to the
ability of cancer cells including MDA-MB-231, MDA-MB-436,
MCF7, and dissociated primary breast cancer cells (DT-16) to
reliably form distant metastatic lesions after primary tumor
formation in the orthotopic mammary fat pad.
Previously, the occurrence of metastasis in mouse models using
human breast cancer cells was sporadic and occurred only at low
rates, even when cells were injected into the tail vein or
administered via the intracardiac route. In BALB/c nude mice,
MDA-MB-231 cells injected into the mammary fat pad yielded no
lung metastases in five mice tested [5]. Only after being ‘‘trained’’
through serial tail-vein injections and harvesting of lung lesions
were the cells able to metastasize from the mammary fat pad, and
then in less than 50% of mice [5].
The more severely immunocompromised NOD SCID mice
have been used to try to obtain a more robust breast cancer
metastasis model. However, metastasis formation by MDA-MB-
231 cells in NOD SCID mice can only generally be accomplished
via tail-vein injection, and not by injection into the orthotopic
mammary fat pad [11]. In addition, the formation of metastases
when MDA-MB-231 cells were injected into the tail-vein was
limited to the lungs.
Human Breast Cancer Metastasis Mouse Model
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When compared to these rates of metastasis, MDA-MB-231
cells in our NSG model form macro-metastases much more
frequently and consistently (axillary lymph nodes 100% of mice,
lungs 100% of mice, liver 78% of mice, and diaphragm 67% of
mice), providing a robust model for the study of human breast
cancer metastasis in mice.
Figure 1. NSG mice consistently develop widespread macro-metastases when MDA-MB-231 cells are injected orthotopically into
the mammary fat pad. A. Volumes of tumors in mammary fat pads of NSG mice injected with MDA-MB-231 cells. Each data point is the mean value
(+/2 s.e.m) of nine primary tumors. B. Micrographs of haematoxylin and eosin (H&E), CK18, EGFR and Her2 IHC staining of harvested MDA-MB-231
primary tumor tissue. MDA-MB-231 primary tumors are CK18 positive, EGFR positive, Her2 negative. C. Quantification of the percentage of mice
bearing macro-metastasis in each organ observed at the time of necropsy (53 days post injection). Macro-metastases were frequently observed in the
left axillary lymph node (100% of mice), lung (100% of mice), liver (78% of mice), diaphragm (67% of mice), and right axillary lymph node (67% of
mice), as well as sporadically in other organs. LN= lymph node. D. Photographs of representative common MDA-MB-231 metastases are shown,
along with micrographs of H&E and CK18 IHC staining of harvested tissue.
doi:10.1371/journal.pone.0047995.g001
Human Breast Cancer Metastasis Mouse Model
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The mechanism(s) limiting cancer cell metastasis in other mouse
models have been frequently debated, and has been hypothesized
to be due to a wide variety of reasons, ranging from the smaller
size of the murine vasculature, to human-mouse signaling
incompatibilities, to selection of non-metastatic subpopulations of
breast cancer cells during culture. Here we show that human
breast cancer cells frequently metastasize in severely immuno-
compromised NSG murine hosts, indicating that the immune
environment (at least partly) determines the metastatic ability of
the human breast cancer cells. NSG mice lack functional B, T and
Natural Killer (NK) cell populations; in contrast, the more
commonly used strains of mice such as nudes and NOD SCID
Figure 2. NSG mice consistently develop macro-metastases when MDA-MB-436 cells are injected orthotopically into the mammary
fat pad. A. Volumes of tumors in mammary fat pads of NSG mice injected with MDA-MB-436 cells. Each data point is the mean value (+/2 s.e.m) of
12 primary tumors. B. Micrographs of haematoxylin and eosin (H&E), CK18, EGFR and Her2 IHC staining of harvested MDA-MB-436 primary tumor
tissue. MDA-MB-436 primary tumors are CK18 positive, EGFR positive, Her2 negative. C. Quantification of the percentage of mice bearing macro-
metastasis in each organ observed at the time of necropsy (43 days post injection). Macro-metastases were frequently observed in the lung (92% of
mice) and left axillary lymph node (75% of mice), as well as sporadically in other organs. LN= lymph node. D. Photographs of representative common
MDA-MB-436 metastases are shown, along with micrographs of H&E and CK18 IHC staining of harvested tissue.
doi:10.1371/journal.pone.0047995.g002
Human Breast Cancer Metastasis Mouse Model
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mice still retain NK (and B cells in the case of nude mice). This
suggests that NSG mice may be inherently susceptible to
metastasis due to the lack of NK cells, demonstrating the
importance of these cells in regulating the metastatic process.
We used the NSG model to identify gene expression changes
that occur in metastatic lesions relative to primary tumors. When
compared, a single gene, LOC100129599, was the most consis-
tently differentially expressed gene at the majority of metastatic
sites relative to primary tumors, in both MDA-MB-231 and MDA-
MB-436 metastatic lesions. LOC100129599, also known as
ribosomal protein S29 pseudogene 14 (RPS29P14), is a pseudo-
gene, and noncoding RNAs transcribed from pseudogenes have
been implicated in tumor progression previously [12]. Thus, it is
possible that altered expression of LOC100129599 may regulate
metastasis and this will be investigated in future experiments.
After obtaining differential expression data from lymph node
and lung metastases relative to primary tumors from two
independent cell lines, we compared these two datasets to identify
commonalities. Six genes, RPL13A, KLF6, LOC100129599,
GBE1, PDGFA, and UHRF1 were altered in lymph node
metastases of both cell lines relative to the primary tumors,
suggesting they may represent changes important for metastatic
growth in lymph nodes.
Literature searches were performed to determine if any of these
genes have previously been implicated in breast cancer lymph
node metastasis. Interestingly, overexpression of PDGFR-a
expression in breast cancer has previously been associated with
lymph node metastasis (P=0.0079) in a cohort of 181 invasive
ductal breast carcinomas patients [13] suggesting that PDGFA
may be clinically relevant for breast cancer lymph node metastasis.
In addition, expression of PGDF has been shown to be associated
Figure 3. NSG mice occasionally develop macro-metastases when MCF7 cells are injected orthotopically into the mammary fat pad.
A. Volumes of tumors in mammary fat pads of NSG mice injected with MCF7 cells. Each data point is the mean value (+/2 s.e.m) of 12 primary
tumors. B. Micrographs of haematoxylin and eosin (H&E), CK18, EGFR and Her2 IHC staining of harvested MCF7 primary tumor tissue. MCF7 primary
tumors are CK18 positive, EGFR negative, Her2 negative. C. Quantification of the percentage of mice bearing macro-metastasis in each organ
observed at the time of necropsy (184 days post injection). Macro-metastases were observed in the left axillary lymph node (67% of mice), lung (25%
of mice), and spleen (25% of mice), as well as sporadically in other organs. LN= lymph node. D. A photograph of an MCF7 kidney metastasis is shown,
along with micrographs of H&E and CK18 IHC staining of harvested tissue.
doi:10.1371/journal.pone.0047995.g003
Human Breast Cancer Metastasis Mouse Model
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with poor clinical outcome in two further studies of breast cancer
patients [14,15]. Evidence supporting a functional role for PDGF
in mediating lymph node metastasis is provided by a study
demonstrating that members of the PDGF family act as
lymphangiogenic factors. In this study, expression of PDGF-BB
induced tumor lymphangiogenesis, leading to enhanced metastasis
in lymph nodes [16].
UHRF1 was also identified from our literature search as a
clinically relevant marker of lymph node metastatic capacity, in
this case in colorectal carcinoma samples. UHRF1 protein
expression was determined in 144 clinical colorectal carcinoma
samples.
UHRF1 protein expression levels correlated with the presence
of lymph nodes (P=0.005), and distal metastasis (P=0.030) [17].
In addition, UHRF1 was shown to induce angiogenesis of MDA-
MB-231 xenografts (assessed by microvessel density) and increase
proliferation, invasion and migration in in vitro assays [18]
suggesting a functional role for UHRF1 in regulating metastasis.
The published demonstration of clinical and functional roles for
two of the genes identified from our microarray analysis of lymph
Figure 4. NSG mice occasionally develop macro-metastases when BT474 cells are injected orthotopically into the mammary fat
pad. A. Volumes of tumors in mammary fat pads of NSG mice injected with BT474 cells. Each data point is the mean value (+/2 s.e.m) of 12 primary
tumors. B. Micrographs of haematoxylin and eosin (H&E), CK18, EGFR and Her2 IHC staining of harvested BT474 primary tumor tissue. BT474 primary
tumors are CK18 positive, EGFR positive, Her2 positive.
doi:10.1371/journal.pone.0047995.g004
Figure 5. Transcriptional changes in MDA-MB-231 and MDA-MB-436 macro-metastases relative to primary tumors. A. Venn diagram
of genes differentially expressed in MDA-MB-231 liver, lung, diaphragm and lymph node metastases compared to primary mammary fat pad tumor
(n = 3 mice per group). One probe (Table S5) is differentially expressed in all metastases compared to the primary mammary fat pad tumor (indicated
by the red circle). Cut offs used for gene list generation: p value with FDR,0.01. B. Venn diagram of genes differentially expressed in MDA-MB-436
lung and lymph node metastases compared to primary mammary fat pad tumor (n = 3 mice per group). 54 probes (Table S8) are differentially
expressed in both lung and lymph node metastases compared to the primary mammary fat pad tumor (indicated by the red circle). Cut offs used for
gene list generation: p value with FDR,0.01. C. Venn diagram of genes differentially expressed in MDA-MB-231 and MDA-MB-436 lymph node
metastases compared to primary mammary fat pad tumors. Six probes (Table S9) are differentially expressed in both lymph node metastases
compared to their respective primary mammary fat pad tumors. D. Venn diagram of genes differentially expressed in MDA-MB-231 and MDA-MB-436
lung metastases compared to primary mammary fat pad tumors. 17 probes (Table S10) are differentially expressed in both lung metastases compared
to their respective primary mammary fat pad tumors.
doi:10.1371/journal.pone.0047995.g005
Human Breast Cancer Metastasis Mouse Model
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node metastases suggests that the changes we have identified may
represent alterations important for metastatic growth in lymph
nodes, and bolsters the relevance of the NSG metastasis model.
Next, the gene expression changes that occurred in lung
metastases relative to primary mammary fat tumor in MDA-MB-
231 xenografts were compared to those that occurred in MDA-
MB-436 xenografts to determine any commonalities. 17 probes
(detecting 16 genes) were altered in lung metastases of both cell
lines relative to primary tumors. Of these 16 genes, RPL14L
(downregulated in lung metastases in both cell lines) has previously
been identified as a candidate breast cancer metastasis regulating
gene [19], and loss of TGFBR2 (downregulated in lung metastases
in both cell lines) has previously been shown to promote metastasis
in mouse models [20]. This suggests that the changes we have
identified may represent alterations important for metastatic
growth in the lung, similarly to the changes we identified for
metastatic growth in lymph nodes.
Previously a lung tropic metastasis signature was identified by
training MDA-MB-231 cells to form lung metastases in nude mice
[5]. We first compared this to our 16 gene lung metastasis
signature (distilled from MDA-MB-231 and MDA-MB-436 data)
to determine if any genes were shared in both signatures.
Interestingly, there were no common genes identified. We next
compared the lung-tropic signature to our 56 gene signature
generated solely from MDA-MB-231 lung metastases. One gene,
collagen, type VI, alpha 1 (COL6A1), was up-regulated in both
MDA-MB-231 signatures. Previous studies have shown that
COL6A1 promotes metastasis [21] so it is likely that COL6A1 is
particularly important for lung metastasis in MDA-MB-231 cells.
It is possible that gene changes facilitating early events in the
metastatic cascade (escape from the primary site, invasion, and
intravasation) that are captured in our orthotopic model are not
represented in the ‘‘trained’’ MDA-MB-231 lung signature, which
may explain why there is not more overlap between the two
signatures.
In summary, the NSG mouse is an important new model for
studying breast cancer metastasis, providing an efficient system to
study the entire metastatic process from the mammary gland using
human cells. This model should facilitate better understanding of
the fundamental mechanisms underlying breast cancer metastasis,
which may ultimately lead to important therapeutic advances.
Experimental Procedures
Ethics statement
The animal experiments described in this study were approved
by the Institutional Animal Care and Use Committee (IACUC) at
the University of Miami (protocol 11–227). All animals were
maintained in accordance with IACUC guidelines.
Cell lines
BT474, MCF7, MDA-MB-231 and MDA-MB-436 human
breast carcinoma cell lines were obtained from the American Type
Culture Collection (Manassas, VA) and maintained according to
the supplier’s instructions. Authentication of the cell lines was
performed by sequencing of the hypervariable regions of the
mitochondrial DNA. DT-16 cells were obtained and cultured as
described previously [10]. Cells were harvested at the exponential
phase of growth for injection into the mammary fat pads of mice.
Animals
NOD scid gamma (NSG) mice were purchased from Jackson
Laboratory. Eight week old female mice were injected unilaterally
with 2.56106 cells in 200 mL of 50:50 Matrigel/Collagen I into the
fourth abdominal fat pad by subcutaneous injection at the base of
the nipple. Tumor growth was monitored externally using vernier
calipers for up to 30 weeks and animals sacrificed when tumors
reached 10% of body weight. Necropsies were performed to
identify macro-metastases. Primary tumors and organs were
harvested, paraffin embedded, sectioned and stained with hema-
toxylin and eosin or antibodies against cytokeratin 18 (CK18),
epidermal growth factor receptor (EGFR), and Her2. Pathology
processing and staining of harvested mouse tissues was performed
at the Lombardi Comprehensive Cancer via Science Exchange,
Inc. Slides were analyzed by a pathologist to confirm the presence
of metastases. RNA was isolated from three independent
metastases and primary xenograft tumors for analysis. Note: No
estrogen pellets were required for growth of estrogen receptor
alpha positive cell lines, MCF7 and BT474.
RNA isolation
RNA was extracted from xenograft primary and metastatic
lesions using Trizol Reagent (Invitrogen) according to the
manufacturer’s instructions. Concentration and yield of RNA
samples were determined using a NanoDrop ND-1000 Spectro-
photometer (NanoDrop Technologies). RNA integrity was deter-
mined by analysis on an Agilent 2100 Bioanalyzer (Agilent
Technologies) following the manufacturer’s recommendations.
Only samples with a RIN score .7.0 were used for microarray
analysis.
Microarray Analysis
The human Illumina gene expression image files obtained from
the Illumina iScan scanner were uploaded to GenomeStudio
(version 2011.1) using the Gene Expression module (v1.9.0). Data
were normalized using the quantile method and the background
was subtracted. Differentially expressed probes were identified
using the Illumina Custom Error Model with Benjamini and
Hochberg False Discovery Rate. A p-value was associated with
every probe (detection p-value) and probes were discarded if this
detection p value was more than 0.05 for all samples. Metastatic
gene expression alterations were determined by identifying genes
differentially expressed between mammary fat pad tumor xeno-
grafts and metastases. The differentially expressed genes from
comparisons were used to create Venn diagrams. Microarray
experiments and analyses of datasets were performed at Wayne
State via Science Exchange, Inc.
Supporting Information
Table S1 Transcripts differentially expressed (p,0.01)
in MDA-MB-231 liver metastases compared to primary
mammary fat pad tumor xenografts in NSG mice (total
420).
(XLSX)
Table S2 Transcripts differentially expressed (p,0.01)
in MDA-MB-231 lung metastases compared to primary
mammary fat pad tumor xenografts in NSG mice (total
56).
(XLSX)
Table S3 Transcripts differentially expressed (p,0.01)
in MDA-MB-231 diaphragm metastases compared to
primary mammary fat pad tumor xenografts in NSG
mice (total 85).
(XLSX)
Table S4 Transcripts differentially expressed (p,0.01)
in MDA-MB-231 lymph node metastases compared to
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primary mammary fat pad tumor xenografts in NSG
mice (total 24).
(XLSX)
Table S5 Venn diagram of genes differentially ex-
pressed in MDA-MB-231 liver, lung, diaphragm and
lymph node metastases compared to primary mamma-
ry fat pad tumor xenografts in NSG mice. 1 probe is
differentially expressed in all metastases compared to the primary
mammary fat pad tumor.
(XLSX)
Table S6 Transcripts differentially expressed (p,0.01)
in MDA-MB-436 lung metastases compared to primary
mammary fat pad tumor xenografts in NSG mice (total
719).
(XLSX)
Table S7 Transcripts differentially expressed (p,0.01)
in MDA-MB-436 lymph node metastases compared to
primary mammary fat pad tumor xenografts in NSG
mice (total 258).
(XLSX)
Table S8 Venn diagram of genes differentially ex-
pressed in MDA-MB-436 lung and lymph node metasta-
ses compared to primary mammary fat pad tumor
xenografts in NSG mice. 54 probes are differentially expressed
in both lung and lymph node metastases compared to the primary
mammary fat pad tumor.
(XLSX)
Table S9 Venn diagram of genes differentially ex-
pressed in MDA-MB-231 and MDA-MB-436 lymph node
metastases compared to primary mammary fat pad
tumors. 6 probes are differentially expressed in both lymph node
metastases compared to their respective primary mammary fat pad
tumors.
(XLSX)
Table S10 Venn diagram of genes differentially ex-
pressed in MDA-MB-231 and MDA-MB-436 lung metas-
tases compared to primary mammary fat pad tumors.
17 probes are differentially expressed in both lung metastases
compared to their respective primary mammary fat pad tumors.
(XLSX)
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